Morning Briefing
Summaries of health policy coverage from major news organizations
There Isn't Enough Data To Justify Banning Breast Implants Linked To Rare Cancer, FDA Decides
A type of breast implant linked to a rare cancer can still be sold in the United States, even though it has been banned in many other countries, the Food and Drug Administration said on Thursday. The implants, which have a textured or slightly roughened surface, as opposed to a smooth covering, have been associated with a cancer of the immune system called anaplastic large-cell lymphoma. The vast majority of the cases have occurred in women with textured implants, mainly those made by Allergan. But the F.D.A. said that the risk, though increased, was still low, and that there was not enough data to justify banning the implants. (Grady and Rabin, 5/2)
In recent years, the FDA and other regulators around the world have grappled with the recently confirmed link to a rare cancer and the thousands of unconfirmed complaints of other health problems that women attribute to the implants, including arthritis, fatigue and muscle pain. FDA regulators said in a statement that while they don't have definitive evidence that implants cause those chronic ailments, women considering implants "should be aware of these risks." To that end, the agency said it will consider adding a boxed warning 鈥 its most serious type 鈥 to breast implants and a checklist describing various potential harms for patients considering them. (Perrone, 5/2)
As of last Sept. 30, the FDA had identified 457 cases of implant-related lymphoma and nine deaths worldwide. The American Society of Plastic Surgeons reported 16 disease-related deaths worldwide as of Jan. 1, 2019. The FDA officials also addressed 鈥渂reast implant illness鈥 a constellation of autoimmune problems that includes joint and muscle pain and allergies and fatigue 鈥 a topic that was repeatedly raised at the March hearing. The agency said it 鈥渄oesn鈥檛 have definitive evidence demonstrating breast implants cause these symptoms,鈥 but added that evidence supports 鈥渢hat some women experience systemic symptoms that may resolve when their breast implants are removed鈥 鈥 and that women should be made aware of the risk before getting implants. (McGinley, 5/2)
The agency said Thursday it doesn鈥檛 have definitive evidence demonstrating implants caused such symptoms, but it said some problems may get better when implants are removed. 鈥淲e believe women considering a breast implant should be aware of these risks.鈥 (Maidenberg and Burton, 5/2)